Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.H.S., Duke University 2001
  • Fellow in Gastroenterology, Medicine, Duke University 1998 - 2000
  • Chief Medical Resident, Medicine, Duke University 1997 - 1998
  • Fellow in Gastroenterology, Medicine, Duke University 1996 - 1997
  • Medical Resident, Medicine, Duke University 1993 - 1996
  • M.D., Duke University 1993
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Gastroenterology, Medicine 2011 - 2016
  • Associate Professor of Medicine, Medicine, Gastroenterology, Medicine 2010 - 2011
  • Assistant Professor of Medicine, Medicine, Gastroenterology, Medicine 2001 - 2009
  • Associate in the Department of Medicine, Medicine, Gastroenterology, Medicine 2000 - 2001
  • Associate in the Department of Medicine, Medicine, Clinical Science Departments 1997 - 1998
• Recognition
• 

  In the News

  • JUN 17, 2015

    WNCN

    Pill-form Hepatitis C treatment giving patients hope

  • MAY 12, 2015

    Interferon-Free Therapy Clears Hepatitis C in 93 Percent of Patients in Trial

  • JUN 13, 2014

    The News & Observer

    New hepatitis C wonder drug shakes up the health care industry
• 

  Awards & Honors

  • Best Medicine Grand Rounds. Duke Department of Medicine. 2011
• Expertise
• 

  Global Scholarship

  • Research

    • United States of America (Country) 
• Research
• 

  Selected Grants

  • CymaBay CB8025-31735 awarded by CymaBay Therapeutics 2019 - 2023
  • Proteus HCV - PB-WOTFORHEPC awarded by Proteus Digital Health, Inc. 2017 - 2022
  • Novartis - AMBER - VAY736 awarded by Novartis Pharmaceuticals Corporation 2018 - 2021
  • Duke Training Grant in Digestive Diseases and Nutrition awarded by National Institutes of Health 1988 - 2021
  • VTEU 13-0053 Task Area C awarded by National Institutes of Health 2014 - 2020
  • Gilead 427-4024 awarded by Gilead Sciences, Inc. 2017 - 2020
  • Gilead 428-4025 awarded by Gilead Sciences, Inc. 2017 - 2020
  • The Impact of Race, Ethnicity, and Socioeconomic Status on Listing for Liver Transplant after Referral awarded by American Association for the Study of Liver Diseases 2018 - 2020
  • Sulfasalazine in PSC awarded by Brigham and Women's Hospital 2018 - 2019
  • TaiwanJ JKB 122AIH awarded by TaiwanJ Pharmaceuticals Co. Ltd 2015 - 2019
  • Smart-C awarded by The Kirby Institute 2018 - 2019
  • HBV Clinical Research Network Site Application_Subcontract to UNC awarded by University of North Carolina - Chapel Hill 2015 - 2019
  • RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse awarded by National Institutes of Health 2013 - 2019
  • An Observational Cohort Study of the Use of Avatrombopag in Patients with Thrombocytopenia Associated with Chronic Liver Disease Undergoing a Procedure awarded by DOVA Pharmaceuticals 2018 - 2019
  • DAA-Salvage Therapy awarded by University of Florida 2017 - 2019
  • Gilead 342-4022 awarded by Gilead Sciences, Inc. 2017 - 2019
  • Heart/Lung Transplant Study awarded by Gilead Sciences, Inc. 2016 - 2019
  • NGM 15-0106 awarded by NGM Biopharmaceuticals, Inc. 2015 - 2019
  • Abbvie M13-596 awarded by AbbVie Inc. 2016 - 2019
  • Gilead 337-1746 awarded by Gilead Sciences, Inc. 2015 - 2018
  • The Impact of Increasing Age on Waiting List and Post-Transplantation Outcomes for NAFLD Patients awarded by American Association for the Study of Liver Diseases 2017 - 2018
  • MK 3682-011 awarded by Merck Sharp & Dohme 2015 - 2017
  • AbbVie M14-868 awarded by AbbVie Inc. 2014 - 2017
  • Merck MK-5172-017-02 awarded by Merck Sharp & Dohme 2015 - 2017
  • Regulation of T cell exhaustion by microRNA-720 awarded by National Institutes of Health 2015 - 2017
  • Merck/MSD MK-5172-065-00 awarded by Merck Sharp & Dohme 2014 - 2017
  • NGM 14-0104 awarded by NGM Biopharmaceuticals 2014 - 2017
  • A Phase 2 open-label study in patients with recurrent Genotype 1 Hepatitis awarded by Janssen Research & Development, LLC 2014 - 2017
  • GS-US-342-1137 awarded by Gilead Sciences, Inc. 2014 - 2017
  • Evidera PSC awarded by Evidera 2014 - 2016
  • BMS AI443-102-0016 A Phase 3 Evaluation awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2013 - 2015
  • BMS Muir, AI443-113 awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2013 - 2015
  • HPN-100-022 awarded by Hyperion Biotechnology, Inc. 2014 - 2015
  • Pilot Study to Assess Changes in Immuneregulation with Phase of Chronic HBV Infection and Antiviral Therapy awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership 2013 - 2015
  • Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients awarded by National Institutes of Health 2011 - 2015
  • VTEU 13-0053 Task Area B awarded by National Institutes of Health 2014 - 2015
  • Patient self-management and gene guided therapy for CHC awarded by National Institutes of Health 2012 - 2015
  • A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir awarded by Gilead Sciences, Inc. 2013 - 2014
  • Gilead GS-US-334-0107 LOI awarded by Gilead Sciences, Inc. 2012
  • Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Use/Abuse awarded by National Institutes of Health 2008 - 2011
  • Uncertainity and Watchful Waiting in Chronic Hepatitis C awarded by National Institutes of Health 2005 - 2009
  • Interferon-y for the treatment of chronic HCV infection awarded by National Institutes of Health 2001 - 2004
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Muir, AJ. "Is Magnetic Resonance Cholangiopancreatography Worth a Thousand Words in Determining Prognoses of Patients With Primary Sclerosing Cholangitis?." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association (May 8, 2019).  Full Text
    • Hirschfield, GM, Chazouillères, O, Drenth, JP, Thorburn, D, Harrison, SA, Landis, CS, Mayo, MJ, Muir, AJ, Trotter, JF, Leeming, DJ, Karsdal, MA, Jaros, MJ, Ling, L, Kim, KH, Rossi, SJ, Somaratne, RM, DePaoli, AM, and Beuers, U. "Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial." Journal of Hepatology 70, no. 3 (March 2019): 483-493.  Full Text
    • Muir, AJ, Levy, C, Janssen, HLA, Montano-Loza, AJ, Shiffman, ML, Caldwell, S, Luketic, V, Ding, D, Jia, C, McColgan, BJ, McHutchison, JG, Mani Subramanian, G, Myers, RP, Manns, M, Chapman, R, Afdhal, NH, Goodman, Z, Eksteen, B, Bowlus, CL, and GS-US-321-0102 Investigators, . "Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease." Hepatology (Baltimore, Md.) 69, no. 2 (February 2019): 684-698.  Full Text
    • Younossi, Z, Stepanova, M, Sanyal, AJ, Harrison, SA, Ratziu, V, Abdelmalek, MF, Diehl, AM, Caldwell, S, Shiffman, ML, Schall, RA, McColgan, B, Subramanian, GM, Myers, RP, Muir, A, Afdhal, NH, Bosch, J, and Goodman, Z. "The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options." Journal of Hepatology 69, no. 6 (December 2018): 1365-1370.  Full Text
    • Harrison, SA, Abdelmalek, MF, Caldwell, S, Shiffman, ML, Diehl, AM, Ghalib, R, Lawitz, EJ, Rockey, DC, Schall, RA, Jia, C, McColgan, BJ, McHutchison, JG, Subramanian, GM, Myers, RP, Younossi, Z, Ratziu, V, Muir, AJ, Afdhal, NH, Goodman, Z, Bosch, J, Sanyal, AJ, and GS-US-321-0105 and GS-US-321-0106 Investigators, . "Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis." Gastroenterology 155, no. 4 (October 2018): 1140-1153.  Full Text
    • Patel, YA, Henson, JB, Wilder, JM, Zheng, J, Chow, S-C, Berg, CL, Knechtle, SJ, and Muir, AJ. "The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis." Clinical Transplantation 32, no. 10 (October 2018): e13388-null.  Full Text
    • Proeschold-Bell, RJ, Evon, DM, Makarushka, C, Wong, JB, Datta, SK, Yao, J, Patkar, AA, Mannelli, P, Hodge, T, Naggie, S, Wilder, JM, Fried, MW, Niedzwiecki, D, and Muir, AJ. "The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial." Contemporary Clinical Trials 72 (September 2018): 73-85.  Full Text
    • Nitsche, B, Miller, SC, Giorgio, M, Berry, CA, and Muir, A. "Improving Hepatitis C Identification: Technology Alone Is Not the Answer." Health Promotion Practice 19, no. 4 (July 2018): 506-512.  Full Text
    • Patel, YA, and Muir, AJ. "Editorial: platelet transfusions in cirrhosis-do the risks outweigh the unclear benefits?." Alimentary Pharmacology & Therapeutics 47, no. 11 (June 2018): 1553-1554.  Full Text
    • Wilder, JM, and Muir, A. "Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations." Expert Opinion on Pharmacotherapy 19, no. 5 (April 2018): 451-456. (Review)  Full Text
    • Collins, LF, Chan, A, Zheng, J, Chow, S-C, Wilder, JM, Muir, AJ, and Naggie, S. "Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection." Open Forum Infectious Diseases 5, no. 1 (January 2018): ofx264-null.  Full Text  Open Access Copy
    • Jou, JH, and Muir, AJ. "Hepatocellular Carcinoma Surveillance." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 16, no. 1 (January 2018): 19-20.  Full Text
    • Tana, MM, and Muir, AJ. "Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 16, no. 1 (January 2018): 16-18.  Full Text
    • Henson, JB, Patel, YA, Wilder, JM, Zheng, J, Chow, S-C, King, LY, and Muir, AJ. "Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis." Digestive Diseases and Sciences 62, no. 11 (November 2017): 3200-3209.  Full Text
    • Patel, YA, Imperial, JC, Muir, AJ, Anstee, QM, DeBrota, D, Dimick-Santos, L, Filozof, C, Mehta, R, Sanyal, AJ, Schabel, E, Neuschwander-Tetri, BA, Miller, V, and Liver Forum’s Data Standardization Working Group, . "Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum." Gastroenterology 153, no. 3 (September 2017): 621-625.e7.  Full Text
    • Sofue, K, Burke, LMB, Nilmini, V, Alagiyawanna, M, Muir, AJ, Choudhury, KR, Jaffe, TA, Semelka, RC, and Bashir, MR. "Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5." Journal of Magnetic Resonance Imaging : Jmri 46, no. 3 (September 2017): 783-792.  Full Text
    • Kwo, PY, Poordad, F, Asatryan, A, Wang, S, Wyles, DL, Hassanein, T, Felizarta, F, Sulkowski, MS, Gane, E, Maliakkal, B, Overcash, JS, Gordon, SC, Muir, AJ, Aguilar, H, Agarwal, K, Dore, GJ, Lin, C-W, Liu, R, Lovell, SS, Ng, TI, Kort, J, and Mensa, FJ. "Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis." Journal of Hepatology 67, no. 2 (August 2017): 263-271.  Full Text
    • Henson, JB, Brown, CL, Chow, S-C, and Muir, AJ. "Complementary and Alternative Medicine Use in United States Adults With Liver Disease." Journal of clinical gastroenterology 51, no. 6 (July 2017): 564-570.  Full Text
    • Henson, JB, Patel, YA, King, LY, Zheng, J, Chow, S-C, and Muir, AJ. "Outcomes of liver retransplantation in patients with primary sclerosing cholangitis." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 23, no. 6 (June 2017): 769-780.  Full Text
    • Singh, S, Muir, AJ, Dieterich, DT, and Falck-Ytter, YT. "American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases." Gastroenterology 152, no. 6 (May 2017): 1544-1577. (Review)  Full Text
    • Bailey, DE, Hendrix, CC, Steinhauser, KE, Stechuchak, KM, Porter, LS, Hudson, J, Olsen, MK, Muir, A, Lowman, S, DiMartini, A, Salonen, LW, and Tulsky, JA. "Randomized trial of an uncertainty self-management telephone intervention for patients awaiting liver transplant." Patient Education and Counseling 100, no. 3 (March 2017): 509-517.  Full Text
    • O'Leary, JG, Fontana, RJ, Brown, K, Burton, JR, Firpi-Morell, R, Muir, A, O'Brien, C, Rabinovitz, M, Reddy, R, Ryan, R, Shprecher, A, Villadiego, S, Prabhakar, A, and Brown, RS. "Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study." Transplant International : Official Journal of the European Society for Organ Transplantation 30, no. 2 (February 2017): 196-208.  Full Text
    • Naggie, S, and Muir, AJ. "Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs." Annual Review of Medicine 68 (January 2017): 345-358. (Review)  Full Text
    • Patel, YA, and Muir, AJ. "Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals." Current hepatology reports 15, no. 4 (December 2016): 285-290.  Full Text
    • Patel, YA, and Muir, AJ. "Mechanisms of Ascites Development-Reply." JAMA 316, no. 17 (November 2016): 1829-. (Letter)  Full Text
    • Brown, CL, Hammill, BG, Qualls, LG, Curtis, LH, and Muir, AJ. "Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare." Journal of Pain and Symptom Management 52, no. 3 (September 2016): 412-419.e1.  Full Text
    • Burke, LMB, Sofue, K, Alagiyawanna, M, Nilmini, V, Muir, AJ, Choudhury, KR, Semelka, RC, and Bashir, MR. "Natural history of liver imaging reporting and data system category 4 nodules in MRI." Abdominal radiology (New York) 41, no. 9 (September 2016): 1758-1766.  Full Text
    • Katrak, S, Park, LP, Woods, C, Muir, A, Hicks, C, and Naggie, S. "Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease." Open forum infectious diseases 3, no. 3 (September 2016): ofw173-.  Full Text
    • Patel, YA, and Muir, AJ. "Evaluation of New-Onset Ascites." JAMA 316, no. 3 (July 2016): 340-341.  Full Text
    • Wilder, JM, Oloruntoba, OO, Muir, AJ, and Moylan, CA. "Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 22, no. 7 (July 2016): 895-905.  Full Text  Open Access Copy
    • Muir, AJ. "State of the State in Gastroenterology." North Carolina medical journal 77, no. 3 (May 2016): 176-179.  Full Text
    • Seña, AC, Willis, SJ, Hilton, A, Anderson, A, Wohl, DA, Hurt, CB, and Muir, AJ. "Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level." Public Health Reports (Washington, D.C. : 1974) 131 Suppl 2 (May 2016): 57-64.  Full Text
    • Sulkowski, MS, Vargas, HE, Di Bisceglie, AM, Kuo, A, Reddy, KR, Lim, JK, Morelli, G, Darling, JM, Feld, JJ, Brown, RS, Frazier, LM, Stewart, TG, Fried, MW, Nelson, DR, Jacobson, IM, and HCV-TARGET Study Group, . "Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection." Gastroenterology 150, no. 2 (February 2016): 419-429.  Full Text
    • Wilder, J, Saraswathula, A, Hasselblad, V, and Muir, A. "A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment." Journal of the National Medical Association 108, no. 1 (February 2016): 24-29. (Review)  Full Text  Open Access Copy
    • Wilder, JM, Jeffers, LJ, Ravendhran, N, Shiffman, ML, Poulos, J, Sulkowski, MS, Gitlin, N, Workowski, K, Zhu, Y, Yang, JC, Pang, PS, McHutchison, JG, Muir, AJ, Howell, C, Kowdley, K, Afdhal, N, and Reddy, KR. "Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data." Hepatology (Baltimore, Md.) 63, no. 2 (February 2016): 437-444.  Full Text  Open Access Copy
    • Oloruntoba, O, and Muir, AJ. "Integrating daclatasvir into hepatitis c therapy." Clinical Liver Disease 7, no. 1 (January 29, 2016): 1-4.  Full Text
    • Curry, MP, O'Leary, JG, Bzowej, N, Muir, AJ, Korenblat, KM, Fenkel, JM, Reddy, KR, Lawitz, E, Flamm, SL, Schiano, T, Teperman, L, Fontana, R, Schiff, E, Fried, M, Doehle, B, An, D, McNally, J, Osinusi, A, Brainard, DM, McHutchison, JG, Brown, RS, Charlton, M, and ASTRAL-4 Investigators, . "Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis." The New England Journal of Medicine 373, no. 27 (December 2015): 2618-2628.  Full Text
    • Muir, AJ, and Naggie, S. "Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 13, no. 12 (November 2015): 2166-2172. (Review)  Full Text
    • Wilder, JM, and Muir, AJ. "Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes." Therapeutic advances in chronic disease 6, no. 6 (November 2015): 314-327. (Review)  Full Text  Open Access Copy
    • Charlton, M, Everson, GT, Flamm, SL, Kumar, P, Landis, C, Brown, RS, Fried, MW, Terrault, NA, O'Leary, JG, Vargas, HE, Kuo, A, Schiff, E, Sulkowski, MS, Gilroy, R, Watt, KD, Brown, K, Kwo, P, Pungpapong, S, Korenblat, KM, Muir, AJ, Teperman, L, Fontana, RJ, Denning, J, Arterburn, S, Dvory-Sobol, H, Brandt-Sarif, T, Pang, PS, McHutchison, JG, Reddy, KR, Afdhal, N, and SOLAR-1 Investigators, . "Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease." Gastroenterology 149, no. 3 (September 2015): 649-659.  Full Text
    • Shuldiner, SR, Gong, L, Muir, AJ, Altman, RB, and Klein, TE. "PharmGKB summary: peginterferon-α pathway." Pharmacogenetics and Genomics 25, no. 9 (September 2015): 465-474.  Full Text
    • Ahmad, T, Yin, P, Saffitz, J, Pockros, PJ, Lalezari, J, Shiffman, M, Freilich, B, Zamparo, J, Brown, K, Dimitrova, D, Kumar, M, Manion, D, Heath-Chiozzi, M, Wolf, R, Hughes, E, Muir, AJ, and Hernandez, AF. "Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C." Hepatology (Baltimore, Md.) 62, no. 2 (August 2015): 409-416.  Full Text
    • Giannini, EG, Afdhal, NH, Sigal, SH, Muir, AJ, Reddy, KR, Vijayaraghavan, S, Elkashab, M, Romero-Gómez, M, Dusheiko, GM, Iyengar, M, Vasey, SY, Campbell, FM, and Theodore, D. "Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy." Journal of Gastroenterology and Hepatology 30, no. 8 (August 2015): 1301-1308.  Full Text
    • Muir, AJ. "Understanding the Complexities of Cirrhosis." Clinical Therapeutics 37, no. 8 (August 2015): 1822-1836. (Review)  Full Text
    • Muir, AJ, Poordad, F, Lalezari, J, Everson, G, Dore, GJ, Herring, R, Sheikh, A, Kwo, P, Hézode, C, Pockros, PJ, Tran, A, Yozviak, J, Reau, N, Ramji, A, Stuart, K, Thompson, AJ, Vierling, J, Freilich, B, Cooper, J, Ghesquiere, W, Yang, R, McPhee, F, Hughes, EA, Swenson, ES, and Yin, PD. "Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis." Jama 313, no. 17 (May 2015): 1736-1744.  Full Text
    • Poordad, F, Sievert, W, Mollison, L, Bennett, M, Tse, E, Bräu, N, Levin, J, Sepe, T, Lee, SS, Angus, P, Conway, B, Pol, S, Boyer, N, Bronowicki, J-P, Jacobson, I, Muir, AJ, Reddy, KR, Tam, E, Ortiz-Lasanta, G, de Lédinghen, V, Sulkowski, M, Boparai, N, McPhee, F, Hughes, E, Swenson, ES, Yin, PD, and UNITY-1 Study Group, . "Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection." Jama 313, no. 17 (May 2015): 1728-1735.  Full Text
    • Flamm, SL, Muir, AJ, Fried, MW, Reddy, KR, Nelson, DR, Bzowej, NH, Sullivan, JC, Bengtsson, L, DeMasi, R, Wright, CI, Kieffer, TL, George, S, Adda, N, and Dusheiko, GM. "Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity." Journal of Clinical Gastroenterology 49, no. 4 (April 2015): 336-344.  Full Text
    • Naggie, S, Patel, K, Yang, L-Y, Chow, S-C, Johnson, V, Guyton, JR, Muir, AJ, Sulkowski, M, and Hicks, C. "Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals." Open forum infectious diseases 2, no. 2 (April 2015): ofv066-.  Full Text
    • Gordon, SC, Muir, AJ, Lim, JK, Pearlman, B, Argo, CK, Ramani, A, Maliakkal, B, Alam, I, Stewart, TG, Vainorius, M, Peter, J, Nelson, DR, Fried, MW, Reddy, KR, and HCV-TARGET study group, . "Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET." Journal of Hepatology 62, no. 2 (February 2015): 286-293.  Full Text
    • Charlton, M, Gane, E, Manns, MP, Brown, RS, Curry, MP, Kwo, PY, Fontana, RJ, Gilroy, R, Teperman, L, Muir, AJ, McHutchison, JG, Symonds, WT, Brainard, D, Kirby, B, Dvory-Sobol, H, Denning, J, Arterburn, S, Samuel, D, Forns, X, and Terrault, NA. "Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation." Gastroenterology 148, no. 1 (January 2015): 108-117.  Full Text
    • Flamm, SL, Muir, AJ, Fried, MW, Reddy, KR, Nelson, DR, Bzowej, NH, Sullivan, JC, Bengtsson, L, DeMasi, R, Wright, CI, Kieffer, TL, George, S, Adda, N, and Dusheiko, GM. "Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity." Journal of Clinical Gastroenterology 49, no. 4 (2015): 336-344.  Full Text
    • Muir, AJ, Arora, S, Everson, G, Flisiak, R, George, J, Ghalib, R, Gordon, SC, Gray, T, Greenbloom, S, Hassanein, T, Hillson, J, Horga, MA, Jacobson, IM, Jeffers, L, Kowdley, KV, Lawitz, E, Lueth, S, Rodriguez-Torres, M, Rustgi, V, Shemanski, L, Shiffman, ML, Srinivasan, S, Vargas, HE, Vierling, JM, Xu, D, Lopez-Talavera, JC, Zeuzem, S, and EMERGE study group, . "A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection." Journal of Hepatology 61, no. 6 (December 2014): 1238-1246.  Full Text
    • Muir, AJ. "Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care." Topics in antiviral medicine 22, no. 4 (September 2014): 685-689. (Review)
    • Clark, PJ, Thompson, AJ, Patel, K, Muir, AJ, and Volk, ML. "Trends in hepatitis C treatment uptake in the United States." Hepatology (Baltimore, Md.) 60, no. 2 (August 2014): 768-769. (Letter)  Full Text
    • Afdhal, N, Zeuzem, S, Kwo, P, Chojkier, M, Gitlin, N, Puoti, M, Romero-Gomez, M, Zarski, J-P, Agarwal, K, Buggisch, P, Foster, GR, Bräu, N, Buti, M, Jacobson, IM, Subramanian, GM, Ding, X, Mo, H, Yang, JC, Pang, PS, Symonds, WT, McHutchison, JG, Muir, AJ, Mangia, A, Marcellin, P, and ION-1 Investigators, . "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection." The New England Journal of Medicine 370, no. 20 (May 2014): 1889-1898.  Full Text
    • Kowdley, KV, Gordon, SC, Reddy, KR, Rossaro, L, Bernstein, DE, Lawitz, E, Shiffman, ML, Schiff, E, Ghalib, R, Ryan, M, Rustgi, V, Chojkier, M, Herring, R, Di Bisceglie, AM, Pockros, PJ, Subramanian, GM, An, D, Svarovskaia, E, Hyland, RH, Pang, PS, Symonds, WT, McHutchison, JG, Muir, AJ, Pound, D, Fried, MW, and ION-3 Investigators, . "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis." The New England Journal of Medicine 370, no. 20 (May 2014): 1879-1888.  Full Text
    • Muir, AJ. "The rapid evolution of treatment strategies for hepatitis C." The American Journal of Gastroenterology 109, no. 5 (May 2014): 628-636. (Review)  Full Text
    • Afdhal, N, Reddy, KR, Nelson, DR, Lawitz, E, Gordon, SC, Schiff, E, Nahass, R, Ghalib, R, Gitlin, N, Herring, R, Lalezari, J, Younes, ZH, Pockros, PJ, Di Bisceglie, AM, Arora, S, Subramanian, GM, Zhu, Y, Dvory-Sobol, H, Yang, JC, Pang, PS, Symonds, WT, McHutchison, JG, Muir, AJ, Sulkowski, M, Kwo, P, and ION-2 Investigators, . "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection." The New England Journal of Medicine 370, no. 16 (April 11, 2014): 1483-1493.  Full Text
    • Melia, MT, Bräu, N, Poordad, F, Lawitz, EJ, Shiffman, ML, McHutchison, JG, Muir, AJ, Galler, GW, Nyberg, LM, Lee, WM, Schiff, E, Long, J, Noviello, S, Brass, CA, Pedicone, LD, and Sulkowski, MS. "Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 58, no. 7 (April 2014): 960-969.  Full Text
    • Vierling, JM, Davis, M, Flamm, S, Gordon, SC, Lawitz, E, Yoshida, EM, Galati, J, Luketic, V, McCone, J, Jacobson, I, Marcellin, P, Muir, AJ, Poordad, F, Pedicone, LD, Albrecht, J, Brass, C, Howe, AYM, Colvard, LY, Helmond, FA, Deng, W, Treitel, M, Wahl, J, and Bronowicki, J-P. "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response." Journal of Hepatology 60, no. 4 (April 2014): 748-756.  Full Text
    • Muir, AJ, Gong, L, Johnson, SG, Lee, MTM, Williams, MS, Klein, TE, Caudle, KE, Nelson, DR, and Clinical Pharmacogenetics Implementation Consortium (CPIC), . "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens." Clinical Pharmacology and Therapeutics 95, no. 2 (February 2014): 141-146.  Full Text
    • Muir, AJ, Gong, L, Johnson, SG, Lee, MTM, Williams, MS, Klein, TE, Caudle, KE, and Nelson, DR. "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-Based Regimens." Clinical Pharmacology and Therapeutics 95, no. 2 (February 1, 2014): 141-146.  Full Text
    • Clark, PJ, Thompson, AJ, Patel, K, Muir, AJ, and Volk, ML. "Trends in hepatitis C treatment uptake in the United States." Hepatology 60, no. 2 (January 1, 2014): 768-769.  Full Text
    • Muir, AJ, Arora, S, Everson, G, Flisiak, R, George, J, Ghalib, R, Gordon, SC, Gray, T, Greenbloom, S, Hassanein, T, Hillson, J, Horga, MA, Jacobson, IM, Jeffers, L, Kowdley, KV, Lawitz, E, Lueth, S, Rodriguez-Torres, M, Rustgi, V, Shemanski, L, Shiffman, ML, Srinivasan, S, Vargas, HE, Vierling, JM, Xu, D, Lopez-Talavera, JC, and Zeuzem, S. "A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection." Journal of Hepatology 61, no. 6 (January 1, 2014): 1238-1246.  Full Text
    • Muir, AJ. "The rapid evolution of treatment strategies for hepatitis C." American Journal of Gastroenterology 109, no. 5 (January 1, 2014): 628-635. (Review)  Full Text
    • Thompson, A, Devine, S, Kattan, M, and Muir, A. "Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin." PLoS ONE 9, no. 8 (January 2014): e103370-.  Full Text
    • Vierling, JM, Davis, M, Flamm, S, Gordon, SC, Lawitz, E, Yoshida, EM, Galati, J, Luketic, V, McCone, J, Jacobson, I, Marcellin, P, Muir, AJ, Poordad, F, Pedicone, LD, Albrecht, J, Brass, C, Howe, AYM, Colvard, LY, Helmond, FA, Deng, W, Treitel, M, Wahl, J, and Bronowicki, JP. "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response." Journal of Hepatology 60, no. 4 (January 1, 2014): 748-756.  Full Text
    • Galmozzi, E, Urban, TJ, Vock, DM, Patel, K, Thompson, AJ, Rumi, MG, D'Ambrosio, R, Muir, AJ, and Colombo, M. "Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy." Journal of Viral Hepatitis 20, no. 12 (December 1, 2013): 858-866.  Full Text
    • Afdhal, NH, Zeuzem, S, Schooley, RT, Thomas, DL, Ward, JW, Litwin, AH, Razavi, H, Castera, L, Poynard, T, Muir, A, Mehta, SH, Dee, L, Graham, C, Church, DR, Talal, AH, Sulkowski, MS, Jacobson, IM, and New Paradigm of HCV Therapy Meeting Participants, . "The new paradigm of hepatitis C therapy: integration of oral therapies into best practices." Journal of Viral Hepatitis 20, no. 11 (November 2013): 745-760. (Review)  Full Text
    • Jazwinski, AB, Clark, PJ, Thompson, AJ, Gordon, SC, Lawitz, EJ, Noviello, S, Brass, CA, Pedicone, LD, Albrecht, JK, Sulkowski, MS, and Muir, AJ. "Predictors of consent to pharmacogenomics testing in the IDEAL study." PHARMACOGENETICS AND GENOMICS 23, no. 11 (November 2013): 619-623.  Full Text  Link to Item
    • Jou, JH, Sulkowski, MS, Noviello, S, Long, J, Pedicone, LD, McHutchison, JG, and Muir, AJ. "Analysis of site performance in academic-based and community-based centers in the IDEAL Study." Journal of Clinical Gastroenterology 47, no. 10 (November 2013): e91-e95.  Full Text
    • Lawitz, E, Lalezari, JP, Hassanein, T, Kowdley, KV, Poordad, FF, Sheikh, AM, Afdhal, NH, Bernstein, DE, Dejesus, E, Freilich, B, Nelson, DR, Dieterich, DT, Jacobson, IM, Jensen, D, Abrams, GA, Darling, JM, Rodriguez-Torres, M, Reddy, KR, Sulkowski, MS, Bzowej, NH, Hyland, RH, Mo, H, Lin, M, Mader, M, Hindes, R, Albanis, E, Symonds, WT, Berrey, MM, and Muir, A. "Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial." The Lancet. Infectious Diseases 13, no. 5 (May 2013): 401-408.  Full Text
    • Luke, FE, Allen, BC, Moshiri, ST, Ho, LM, Massey, CM, Stinnett, SS, Muir, AJ, and Jaffe, TA. "Multiphase multi-detector row computed tomography in the setting of chronic liver disease and orthotopic liver transplantation: can a series be eliminated in order to reduce radiation dose?." J Comput Assist Tomogr 37, no. 3 (May 2013): 408-414.  Full Text  Link to Item
    • Northup, PG, Argo, CK, Muir, AJ, Decross, AJ, Coyle, WJ, and Oxentenko, AS. "Procedural competency of gastroenterology trainees: from apprenticeship to milestones." Gastroenterology 144, no. 4 (April 2013): 677-680.  Full Text
    • Aronsohn, A, Muir, AJ, Swan, T, and Jensen, D. "Is the HCV pipeline heading in the right direction?." Gastroenterology 144, no. 3 (March 2013): 482-485.  Full Text
    • Muir, AJ. "IL28B in the era of direct-acting antivirals for hepatitis C." Journal of Clinical Gastroenterology 47, no. 3 (March 2013): 222-227. (Review)  Full Text
    • Bailey, RK, Muir, AJ, Howell, CD, Bright, C, Roane, PR, Teshale, E, Johnson, CM, Curry, SB, Collins, AC, Jordan, W, and Allison-Ottey, SD. "The hepatitis C crisis in the African American Community: findings and recommendations." Journal of the National Medical Association 105, no. 2 (January 2013): 108-111. (Review)  Full Text
    • Clark, PJ, Aghemo, A, Degasperi, E, Galmozzi, E, Urban, TJ, Vock, DM, Patel, K, Thompson, AJ, Rumi, MG, D'Ambrosio, R, and al, E. "Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy." Journal of Viral Hepatitis (2013).  Full Text
    • Jou, JH, Sulkowski, MS, Noviello, S, Long, J, Pedicone, LD, Mchutchison, JG, and Muir, AJ. "Analysis of site performance in academic-based and community-based centers in the IDEAL study." Journal of Clinical Gastroenterology 47, no. 10 (2013): e91-e95.  Full Text
    • Jou, JH, and Muir, AJ. "Hepatitis C." Annals of Internal Medicine 157, no. 11 (December 10, 2012): 1-16.
    • Jou, JH, and Muir, AJ. "In the clinic. Hepatitis C." Annals of Internal Medicine 157, no. 11 (December 2012): ITC6-1 - ITC6-16-null. (Review)  Full Text
    • Muir, AJ. "Approach to the treatment-naïve patient with HCV genotype 1 infection." Infect Dis Clin North Am 26, no. 4 (December 2012): 893-901. (Review)  Full Text  Link to Item
    • Clark, PJ, Thompson, AJ, Zhu, Q, Vock, DM, Zhu, M, Patel, K, Harrison, SA, Naggie, S, Ge, D, Tillmann, HL, Urban, TJ, Shianna, K, Fellay, J, Goodman, Z, Noviello, S, Pedicone, LD, Afdhal, N, Sulkowski, M, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Muir, AJ. "Erratum: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis c infection (Digestive Diseases and Sciences (2012) 57 (2479))." Digestive Diseases and Sciences 57, no. 9 (September 1, 2012): 2479-null.  Full Text
    • Gellad, ZF, Muir, AJ, McHutchison, JG, Sievert, W, Sharara, AI, Brown, KA, Flisiak, R, Jacobson, IM, Kershenobich, D, Manns, MP, Schulman, KA, and Reed, SD. "Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response." Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research 15, no. 6 (September 2012): 876-886.  Full Text
    • Norton, BL, Park, L, McGrath, LJ, Proeschold Bell, RJ, Muir, AJ, and Naggie, S. "Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection." Aids Patient Care and Stds 26, no. 9 (September 2012): 541-545.  Full Text
    • Clark, PJ, Thompson, AJ, Zhu, Q, Vock, DM, Zhu, M, Patel, K, Harrison, SA, Naggie, S, Ge, D, Tillmann, HL, Urban, TJ, Shianna, K, Fellay, J, Goodman, Z, Noviello, S, Pedicone, LD, Afdhal, N, Sulkowski, M, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Muir, AJ. "The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection." Dig Dis Sci 57, no. 8 (August 2012): 2213-2221.  Full Text  Link to Item
    • Naggie, S, Osinusi, A, Katsounas, A, Lempicki, R, Herrmann, E, Thompson, AJ, Clark, PJ, Patel, K, Muir, AJ, McHutchison, JG, Schlaak, JF, Trippler, M, Shivakumar, B, Masur, H, Polis, MA, and Kottilil, S. "Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response." Hepatology (Baltimore, Md.) 56, no. 2 (August 2012): 444-454.  Full Text
    • Clark, PJ, Thompson, AJ, Vock, DM, Kratz, LE, Tolun, AA, Muir, AJ, McHutchison, JG, Subramanian, M, Millington, DM, Kelley, RI, and Patel, K. "Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner." Hepatology 56, no. 1 (July 2012): 49-56.  Full Text  Link to Item
    • Clark, PJ, and Muir, AJ. "Overcoming barriers to care for hepatitis C." N Engl J Med 366, no. 26 (June 28, 2012): 2436-2438.  Full Text  Link to Item
    • Clark, PJ, Thompson, AJ, Zhu, M, Vock, DM, Zhu, Q, Ge, D, Patel, K, Harrison, SA, Urban, TJ, Naggie, S, Fellay, J, Tillmann, HL, Shianna, K, Noviello, S, Pedicone, LD, Esteban, R, Kwo, P, Sulkowski, MS, Afdhal, N, Albrecht, JK, Goldstein, DB, McHutchison, JG, Muir, AJ, and IDEAL investigators, . "Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response." J Viral Hepat 19, no. 5 (May 2012): 332-340.  Full Text  Link to Item
    • Muir, AJ. "Surgical clearance for the patient with chronic liver disease." Clin Liver Dis 16, no. 2 (May 2012): 421-433. (Review)  Full Text  Link to Item
    • Proeschold-Bell, RJ, Patkar, AA, Naggie, S, Coward, L, Mannelli, P, Yao, J, Bixby, P, and Muir, AJ. "An integrated alcohol abuse and medical treatment model for patients with hepatitis C." Dig Dis Sci 57, no. 4 (April 2012): 1083-1091.  Full Text  Open Access Copy  Link to Item
    • Jazwinski, A, and Muir, A. "IL28B: Implications for clinical practice." Current Hepatitis Reports 11, no. 1 (March 1, 2012): 15-22. (Review)  Full Text
    • Thompson, AJ, Clark, PJ, Muir, AJ, and Sulkowski, MS. "Reply to "iL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?"." Journal of Hepatology 56, no. 3 (March 1, 2012): 742-743. (Letter)  Full Text
    • Thompson, AJ, Clark, PJ, Singh, A, Ge, D, Fellay, J, Zhu, M, Zhu, Q, Urban, TJ, Patel, K, Tillmann, HL, Naggie, S, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, EJ, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Shianna, KV, Noviello, S, Pedicone, LD, Brass, CA, Albrecht, JK, Sulkowski, MS, Goldstein, DB, McHutchison, JG, and Muir, AJ. "Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients." Journal of Hepatology 56, no. 2 (February 2012): 313-319.  Full Text
    • Clark, PJ, and Muir, AJ. "Lost in translation? IL28B's discovery and the journey back to the patient." Hepatology 56, no. 1 (2012): 5-8.  Full Text
    • Gellad, ZF, Reed, SD, and Muir, AJ. "Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C." Antiviral Therapy 17, no. 6 Pt B (January 2012): 1189-1199. (Review)  Full Text
    • Vock, DM, Davidian, M, Tsiatis, AA, and Muir, AJ. "Mixed model analysis of censored longitudinal data with flexible random-effects density." Biostatistics 13, no. 1 (January 2012): 61-73.  Full Text  Link to Item
    • Muir, AJ. "Telaprevir for the treatment of chronic hepatitis C infection." Expert Rev Anti Infect Ther 9, no. 12 (December 2011): 1105-1114. (Review)  Full Text  Link to Item
    • Tillmann, HL, Patel, K, Muir, AJ, Guy, CD, Li, JH, Lao, XQ, Thompson, A, Clark, PJ, Gardner, SD, McHutchison, JG, and McCarthy, JJ. "Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C." J Hepatol 55, no. 6 (December 2011): 1195-1200.  Full Text  Link to Item
    • "HCV and Racial Differences." (November 3, 2011): 185-189. (Chapter)  Full Text
    • Muir, AJ, Poordad, FF, McHutchison, JG, Shiffman, ML, Berg, T, Ferenci, P, Heathcote, EJ, Pawlotsky, J-M, Zeuzem, S, Reesink, HW, Dusheiko, G, Martin, EC, George, S, Kauffman, RS, and Adda, N. "Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response." Hepatology 54, no. 5 (November 2011): 1538-1546.  Full Text  Link to Item
    • Proeschold-Bell, RJ, Hoeppner, B, Taylor, B, Cohen, S, Blouin, R, Stringfield, B, and Muir, AJ. "An interrupted time series evaluation of a hepatitis C intervention for persons with HIV." Aids Behav 15, no. 8 (November 2011): 1721-1731.  Full Text  Link to Item
    • Jazwinski, AB, and Muir, AJ. "Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals." Gastroenterol Clin North Am 40, no. 3 (September 2011): 481-494. (Review)  Full Text  Link to Item
    • Melia, MT, Muir, AJ, McCone, J, Shiffman, ML, King, JW, Herrine, SK, Galler, GW, Bloomer, JR, Nunes, FA, Brown, KA, Mullen, KD, Ravendhran, N, Ghalib, RH, Boparai, N, Jiang, R, Noviello, S, Brass, CA, Albrecht, JK, McHutchison, JG, Sulkowski, MS, and IDEAL Study Team, . "Racial differences in hepatitis C treatment eligibility." Hepatology (Baltimore, Md.) 54, no. 1 (July 2011): 70-78.  Full Text
    • Jacobson, IM, McHutchison, JG, Dusheiko, G, Di Bisceglie, AM, Reddy, KR, Bzowej, NH, Marcellin, P, Muir, AJ, Ferenci, P, Flisiak, R, George, J, Rizzetto, M, Shouval, D, Sola, R, Terg, RA, Yoshida, EM, Adda, N, Bengtsson, L, Sankoh, AJ, Kieffer, TL, George, S, Kauffman, RS, Zeuzem, S, and ADVANCE Study Team, . "Telaprevir for previously untreated chronic hepatitis C virus infection." The New England Journal of Medicine 364, no. 25 (June 2011): 2405-2416.  Full Text
    • Muir, AJ. "The protease inhibitor era: an opportunity to improve the quality of care." Dig Dis Sci 56, no. 5 (May 2011): 1252-1254.  Full Text  Link to Item
    • Muir, AJ, Hu, K-Q, Gordon, SC, Koury, K, Boparai, N, Noviello, S, Albrecht, JK, Sulkowski, MS, and McCone, J. "Hepatitis C treatment among racial and ethnic groups in the IDEAL trial." Journal of Viral Hepatitis 18, no. 4 (April 2011): e134-e143.  Full Text
    • Poordad, F, McCone, J, Bacon, BR, Bruno, S, Manns, MP, Sulkowski, MS, Jacobson, IM, Reddy, KR, Goodman, ZD, Boparai, N, DiNubile, MJ, Sniukiene, V, Brass, CA, Albrecht, JK, Bronowicki, JP, Colombato, L, Curciarello, J, Silva, M, Tanno, H, Terg, R, Adler, M, Langlet, P, Lasser, L, Nevens, F, Anderson, F, Bailey, R, Bilodeau, M, Cooper, C, Feinman, SV, Heathcote, J, Levstik, M, Ramji, A, Sherman, M, Shafran, S, Yoshida, E, Achim, A, Ben Ali, S, Bigard, MA, Bonny, C, Bourliere, M, Boyer-Darrigrand, N, Canva, V, Couzigou, P, De Ledinghen, V, Guyader, D, Hezode, C, Larrey, D, Latournerie, M, Marcellin, P, Mathurin, P, Maynard-Muet, M, Moussalli, J, Poupon, R, Poynard, T, Serfaty, L, Tran, A, Trepo, C, Truchi, R, Zarski, JP, Berg, T, Dikopoulos, N, Eisenbach, C, Galle, PR, Gerken, G, Goeser, T, Gregor, M, Klass, D, Kraus, MR, Niederau, C, Schlaak, JF, Schmid, R, Thies, P, Schmidt, K, Thimme, R, Weidenbach, H, Zeuzem, S, Angelico, M, Carosi, G, Craxì, A, Mangia, A, Pirisi, M, Rizzetto, M, Taliani, G, Zignego, AL, Reesink, HW, Serejo, F, Reymunde, A, Rosado, B, Torres, E, Barcena Marugan, R, De La Mata, M, Calleja, JL, Castellano, G, Diago, M, Esteban, R, Fernandez-Rodriguez, C, Sanchez Tapias, J, Serra Desfilis, MA, Afdhal, N, and Al-Osaimi, A. "Boceprevir for untreated chronic HCV genotype 1 infection." New England Journal of Medicine 364, no. 13 (March 31, 2011): 1195-1206.  Full Text
    • Clark, PJ, Thompson, AJV, and Muir, AJ. "IL28B polymorphisms and treatment of hepatitis C." Current Hepatitis Reports 10, no. 1 (March 1, 2011): 70-78. (Review)  Full Text
    • Jazwinski, AB, and Muir, AJ. "Direct-acting antiviral medications for chronic hepatitis C virus infection." Gastroenterol Hepatol (N Y) 7, no. 3 (March 2011): 154-162.  Link to Item
    • Thompson, AJ, Santoro, R, Piazzolla, V, Clark, PJ, Naggie, S, Tillmann, HL, Patel, K, Muir, AJ, Shianna, KV, Mottola, L, Petruzzellis, D, Romano, M, Sogari, F, Facciorusso, D, Goldstein, DB, McHutchison, JG, and Mangia, A. "Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR." Hepatology (Baltimore, Md.) 53, no. 2 (February 2011): 389-395.  Full Text
    • Jou, JH, Chen, P-H, Jazwinski, A, Bouneva, I, Smith, AD, and Muir, AJ. "Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center." Digestive Diseases and Sciences 55, no. 12 (December 2010): 3591-3596.  Full Text
    • Thompson, AJ, Muir, AJ, Sulkowski, MS, Patel, K, Tillmann, HL, Clark, PJ, Naggie, S, Fellay, J, Ge, D, McCarthy, JJ, Goldstein, DB, and McHutchison, JG. "Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype." Hepatology (Baltimore, Md.) 52, no. 6 (December 2010): 2243-2244. (Letter)  Full Text
    • Thompson, AJ, Santoro, R, Piazzolla, V, Clark, PJ, Naggie, S, Tillmann, HL, Patel, K, Muir, AJ, Shianna, KV, Mottola, L, Petruzzellis, D, Romano, M, Sogari, F, Facciorusso, D, Goldstein, DB, McHutchison, JG, and Mangia, A. "Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR." Hepatology (November 12, 2010).  Full Text  Link to Item
    • Bailey, DE, Barroso, J, Muir, AJ, Sloane, R, Richmond, J, McHutchison, J, Patel, K, Landerman, L, and Mishel, MH. "Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue." Res Nurs Health 33, no. 5 (October 2010): 465-473.  Full Text  Link to Item
    • Poordad, F, Lawitz, E, Shiffman, ML, Hassanein, T, Muir, AJ, Bacon, BR, Heise, J, Halliman, D, Chun, E, and Hammond, J. "Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C." Hepatology (Baltimore, Md.) 52, no. 4 (October 2010): 1208-1215.  Full Text
    • Thompson, AJ, Fellay, J, Patel, K, Tillmann, HL, Naggie, S, Ge, D, Urban, TJ, Shianna, KV, Muir, AJ, Fried, MW, Afdhal, NH, Goldstein, DB, and McHutchison, JG. "Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction." Gastroenterology 139, no. 4 (October 2010): 1181-1189.  Full Text
    • Zeuzem, S, Sulkowski, MS, Lawitz, EJ, Rustgi, VK, Rodriguez-Torres, M, Bacon, BR, Grigorescu, M, Tice, AD, Lurie, Y, Cianciara, J, Muir, AJ, Cronin, PW, Pulkstenis, E, Subramanian, GM, McHutchison, JG, and ACHIEVE-1 Study Team, . "Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1." Gastroenterology 139, no. 4 (October 2010): 1257-1266.  Full Text
    • Muir, AJ, Shiffman, ML, Zaman, A, Yoffe, B, de la Torre, A, Flamm, S, Gordon, SC, Marotta, P, Vierling, JM, Lopez-Talavera, JC, Byrnes-Blake, K, Fontana, D, Freeman, J, Gray, T, Hausman, D, Hunder, NN, and Lawitz, E. "Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection." Hepatology 52, no. 3 (September 2010): 822-832.  Full Text  Link to Item
    • Anderson, AM, Mosunjac, MB, Palmore, MP, Osborn, MK, and Muir, AJ. "Development of fatal acute liver failure in HIV-HBV coinfected patients." World J Gastroenterol 16, no. 32 (August 28, 2010): 4107-4111.  Link to Item
    • Castor, JM, Wood, RK, Muir, AJ, Palmer, SM, and Shimpi, RA. "Gastroesophageal reflux and altered motility in lung transplant rejection." Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society 22, no. 8 (August 2010): 841-850. (Review)  Full Text
    • Richmond, JA, Bailey, DE, Patel, K, Jezsik, JA, Muir, A, Lin, J-R, Chow, S-C, Uzarski, D, and McHutchison, JG. "The use of complementary and alternative medicine by patients with chronic hepatitis C." Complementary Therapies in Clinical Practice 16, no. 3 (August 2010): 124-131.  Full Text
    • Proeschold-Bell, RJ, Blouin, R, Reif, S, Amana, A, Rowland, BJ, Lombard, F, Stringfield, B, and Muir, AJ. "Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV." South Med J 103, no. 7 (July 2010): 635-641.  Full Text  Link to Item
    • Thompson, AJ, Muir, AJ, Sulkowski, MS, Ge, D, Fellay, J, Shianna, KV, Urban, T, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, EJ, McCone, J, Shiffman, ML, Galler, GW, Lee, WM, Reindollar, R, King, JW, Kwo, PY, Ghalib, RH, Freilich, B, Nyberg, LM, Zeuzem, S, Poynard, T, Vock, DM, Pieper, KS, Patel, K, Tillmann, HL, Noviello, S, Koury, K, Pedicone, LD, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus." Gastroenterology 139, no. 1 (July 2010): 120-9.e18.  Full Text
    • Li, JH, Lao, XQ, Tillmann, HL, Rowell, J, Patel, K, Thompson, A, Suchindran, S, Muir, AJ, Guyton, JR, Gardner, SD, McHutchison, JG, and McCarthy, JJ. "Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection." Hepatology 51, no. 6 (June 2010): 1904-1911.  Full Text  Link to Item
    • McCarthy, JJ, Li, JH, Thompson, A, Suchindran, S, Lao, XQ, Patel, K, Tillmann, HL, Muir, AJ, and McHutchison, JG. "Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin." Gastroenterology 138, no. 7 (June 2010): 2307-2314.  Full Text
    • Castellino, S, Muir, A, Shah, A, Shope, S, McMullen, K, Ruble, K, Barber, A, Davidoff, A, and Hudson, MM. "Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group." Pediatric Blood & Cancer 54, no. 5 (May 2010): 663-669. (Review)  Full Text
    • Muir, AJ. "Telaprevir in the treatment of patients with genotype 1 hepatitis C." Gastroenterology and Hepatology 6, no. 5 (May 1, 2010): 303-305.
    • Richmond, JA, Bailey, DE, McHutchison, JG, and Muir, AJ. "The use of mind-body medicine and prayer among adult patients with chronic hepatitis C." Gastroenterol Nurs 33, no. 3 (May 2010): 210-216.  Full Text  Link to Item
    • McHutchison, JG, Manns, MP, Muir, AJ, Terrault, NA, Jacobson, IM, Afdhal, NH, Heathcote, EJ, Zeuzem, S, Reesink, HW, Garg, J, Bsharat, M, George, S, Kauffman, RS, Adda, N, Di Bisceglie, AM, and PROVE3 Study Team, . "Telaprevir for previously treated chronic HCV infection." The New England Journal of Medicine 362, no. 14 (April 2010): 1292-1303.  Full Text
    • Fellay, J, Thompson, AJ, Ge, D, Gumbs, CE, Urban, TJ, Shianna, KV, Little, LD, Qiu, P, Bertelsen, AH, Watson, M, Warner, A, Muir, AJ, Brass, C, Albrecht, J, Sulkowski, M, McHutchison, JG, and Goldstein, DB. "ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C." Nature 464, no. 7287 (March 2010): 405-408.  Full Text
    • Hantouche, E, Kirkiacharian, S, McHutchison, JG, Mann, MP, Muir, AJ, Trudel, E, Bourque, CW, Thomas Vierbuchen, T, Ostermeier, A, Pang, ZP, Thirukkumaran, CM, Nodwell, MJ, Hirasawa, K, Toshinori Yoshida, T, Mett, I, Bhunia, AK, Smitaman, E, Rubinowitz, A, Gupta, R, Lavollay, M, Mainardi, JL, Madhi, S, and Cunliffe, N. "Editorial: Accreditation: The Revue Francophone des Laboratoires seeks dialogue." Revue Francophone Des Laboratoires 2010, no. 423 (January 1, 2010): 3-null.  Full Text
    • Naudin, C, Hantouche, E, Kirkiacharian, S, McHutchison, JG, Mann, MP, Muir, AJ, Trudel, E, Bourque, CW, Thomas Vierbuchen, T, Ostermeier, A, Pang, ZP, Thirukkumaran, CM, Nodwell, MJ, Hirasawa, K, Toshinori Yoshida, T, Mett, I, Bhunia, AK, Smitaman, E, Rubinowitz, A, Gupta, R, Lavollay, M, Mainardi, JL, Madhi, S, and Cunliffe, N. "Accreditation: What you want to know - Abusus non tollit usum. An interview with Drs. Anne-Marie Gallot and Michel Ballereau." Revue Francophone Des Laboratoires 2010, no. 423 (January 1, 2010): 8-13.  Full Text
    • Naudin, C, Hantouche, E, Kirkiacharian, S, McHutchison, JG, Mann, MP, Muir, AJ, Trudel, E, Bourque, CW, Thomas Vierbuchen, T, Ostermeier, A, Pang, ZP, Thirukkumaran, CM, Nodwell, MJ, Hirasawa, K, Toshinori Yoshida, T, Mett, I, Bhunia, AK, Smitaman, E, Rubinowitz, A, Gupta, R, Lavollay, M, Mainardi, JL, Madhi, S, and Cunliffe, N. "Ortho Clinical Diagnostics: Scientific knowledge influences our way of life." Revue Francophone Des Laboratoires 2010, no. 423 (January 1, 2010): 14-16.  Full Text
    • Ge, D, Fellay, J, Thompson, AJ, Simon, JS, Shianna, KV, Urban, TJ, Heinzen, EL, Qiu, P, Bertelsen, AH, Muir, AJ, Sulkowski, M, McHutchison, JG, and Goldstein, DB. "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance." Nature 461, no. 7262 (September 2009): 399-401.  Full Text
    • McHutchison, JG, Lawitz, EJ, Shiffman, ML, Muir, AJ, Galler, GW, McCone, J, Nyberg, LM, Lee, WM, Ghalib, RH, Schiff, ER, Galati, JS, Bacon, BR, Davis, MN, Mukhopadhyay, P, Koury, K, Noviello, S, Pedicone, LD, Brass, CA, Albrecht, JK, Sulkowski, MS, and IDEAL Study Team, . "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection." The New England Journal of Medicine 361, no. 6 (August 2009): 580-593.  Full Text
    • McHutchison, JG, Everson, GT, Gordon, SC, Jacobson, IM, Sulkowski, M, Kauffman, R, McNair, L, Alam, J, Muir, AJ, and PROVE1 Study Team, . "Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection." The New England Journal of Medicine 360, no. 18 (April 2009): 1827-1838.  Full Text
    • Bailey, DE, Landerman, L, Barroso, J, Bixby, P, Mishel, MH, Muir, AJ, Strickland, L, and Clipp, E. "Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C." Psychosomatics 50, no. 2 (March 2009): 138-146.  Full Text
    • Nelson, DR, Rustgi, V, Balan, V, Sulkowski, MS, Davis, GL, Muir, AJ, Lambiase, LR, Dickson, RC, Weisner, RH, Fiscella, M, Cronin, PW, Pulkstenis, E, McHutchison, JG, and Subramanian, GM. "Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 7, no. 2 (February 2009): 212-218.  Full Text
    • Moylan, CA, Brady, CW, Johnson, JL, Smith, AD, Tuttle-Newhall, JE, and Muir, AJ. "Disparities in liver transplantation before and after introduction of the MELD score." Jama 300, no. 20 (November 2008): 2371-2378.  Full Text
    • Canlas, KR, Dobozi, BM, Lin, S, Smith, AD, Rockey, DC, Muir, AJ, Agrawal, NM, Poleski, MH, Patel, K, and McHutchison, JG. "Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia." J Clin Gastroenterol 42, no. 7 (August 2008): 844-848.  Full Text  Link to Item
    • Lawitz, E, Rodriguez-Torres, M, Muir, AJ, Kieffer, TL, McNair, L, Khunvichai, A, and McHutchison, JG. "Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients." Journal of Hepatology 49, no. 2 (August 2008): 163-169.  Full Text
    • Jou, JH, and Muir, AJ. "In the clinic. Hepatitis C." Ann Intern Med 148, no. 11 (June 3, 2008): ITC6-1-ITC6-16-. (Review)  Full Text  Link to Item
    • Brady, CW, Smith, AD, Stechuchak, KM, Coffman, CJ, Tuttle-Newhall, JE, Provenzale, D, and Muir, AJ. "Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era." Liver Transpl 14, no. 2 (February 2008): 228-234.  Full Text  Link to Item
    • Weegink, CJ, Forestier, N, Jansen, PL, Zeuzem, S, Reesink, HW, Jacobson, IM, Everson, GT, Gordon, SC, Kauffman, R, McNair, L, Muir, A, McHutchison, JG, Hezode, C, Ferenci, P, Dusheiko, GM, Pol, S, Goeser, T, Bronowicki, JP, Gharakhanian, S, Devonish, D, Alam, J, Pawlotsky, JM, Kieffer, T, Zhou, Y, Zhang, E, Marcial, M, Byrn, R, Pfeiffer, T, Miller, J, Tigges, A, Bartels, D, Kwong, A, Dusheiko, G, Standring, DN, Bichko, V, Chase, R, LaColla, M, Lallos, L, Skelton, A, Soukasakos, M, Tausek, M, Tong, X, Ralston, R, Poordad, F, Lawitz, EJ, Gitlin, N, Rodriguez-Torres, M, Box, T, Nguyen, T, Pietropaolo, K, Liu, W, Fielman, BA, Mayers, D, Pockros, PJ, Nelson, D, Godofsky, E, Everson, G, Fried, MW, Ghalib, RH, Harrison, SA, Nyberg, LM, Shiffman, ML, Hill, GZ, and Chan, A. "Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection." Gastroenterology and Hepatology 4, no. 2 SUPPL. 6 (February 1, 2008): 5-13.
    • Muir, AJ. "Immunosuppressive Medications." (December 13, 2007): 503-521. (Chapter)  Full Text
    • Gellad, ZF, Alexander, BD, Liu, JK, Griffith, BC, Meyer, AM, Johnson, JL, and Muir, AJ. "Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients." Transpl Infect Dis 9, no. 4 (December 2007): 276-280.  Full Text  Link to Item
    • McHutchison, JG, Bacon, BR, Gordon, SC, Lawitz, E, Shiffman, M, Afdhal, NH, Jacobson, IM, Muir, A, Al-Adhami, M, Morris, ML, Lekstrom-Himes, JA, Efler, SM, and Davis, HL. "Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus." Hepatology (Baltimore, Md.) 46, no. 5 (November 2007): 1341-1349.  Full Text
    • Branagan, N, and Muir, AJ. "Hepatitis C - Current advances in therapy." Practical Gastroenterology 31, no. 8 (August 1, 2007): 20-29. (Review)
    • Muir, AJ, and McHutchison, JG. "Growth factors during HCV therapy may be "cost-effective", but are they "effective"?." Hepatology 44, no. 6 (December 2006): 1400-1403.  Full Text  Link to Item
    • Ramamurthy, M, and Muir, AJ. "Treatment of hepatitis C in special populations." Clinics in Liver Disease 10, no. 4 (November 2006): 851-865. (Review)  Full Text
    • Scales, CD, Fein, S, Muir, AJ, and Rockey, DC. "Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission." J Clin Gastroenterol 40, no. 10 (November 2006): 913-918.  Full Text  Link to Item
    • Heneghan, MA, Allan, ML, Bornstein, JD, Muir, AJ, and Tendler, DA. "Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis." J Hepatol 45, no. 4 (October 2006): 584-591.  Full Text  Link to Item
    • Brady, CW, and Muir, AJ. "The impact of race and ethnicity on the treatment of hepatitis C disease." Current Hepatitis Reports 5, no. 3 (August 1, 2006): 79-85. (Review)  Full Text
    • Muir, AJ, Sylvestre, PB, and Rockey, DC. "Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection." Journal of Viral Hepatitis 13, no. 5 (May 2006): 322-328.  Full Text
    • Patel, K, Muir, AJ, and McHutchison, JG. "Diagnosis and treatment of chronic hepatitis C infection." Bmj (Clinical Research Ed.) 332, no. 7548 (April 2006): 1013-1017. (Review)  Full Text
    • Muir, AJ. "HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?." Nature Clinical Practice. Gastroenterology & Hepatology 2, no. 12 (December 2005): 568-569.  Full Text
    • Moylan, CA, and Muir, AJ. "Treatment of hepatitis C in special populations." Clin Liver Dis 9, no. 4 (November 2005): 567-v. (Review)  Full Text  Link to Item
    • Brady, CW, and Muir, AJ. "HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis." Hepatology 42, no. 2 (August 2005): 496-497. (Letter)  Full Text  Link to Item
    • Condron, SL, Heneghan, MA, Patel, K, Dev, A, McHutchison, JG, and Muir, AJ. "Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection." Transplantation 80, no. 1 (July 15, 2005): 145-148.  Link to Item
    • Smith, AD, Bai, D, Marroquin, CE, Tuttle-Newhall, JE, Desai, DM, Collins, BH, Muir, A, Kuo, PC, McHutchison, J, and Rockey, DC. "Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus." Clin Transplant 19, no. 2 (April 2005): 250-254.  Full Text  Link to Item
    • Balan, V, Schwartz, D, Wu, GY, Muir, AJ, Ghalib, R, Jackson, J, Keeffe, EB, Rossaro, L, Burnett, A, Goon, BL, Bowers, PJ, Leitz, GJ, and HCV Natural History Study Group, . "Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin." The American Journal of Gastroenterology 100, no. 2 (February 2005): 299-307.  Full Text
    • Moriguchi, H, and Sato, C. "Treatment of chronic hepatitis C in blacks and non-Hispanic whites." The New England Journal of Medicine 351, no. 8 (August 2004): 831-832. (Letter)  Full Text
    • Muir, AJ, Bornstein, JD, Killenberg, PG, and Atlantic Coast Hepatitis Treatment Group, . "Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites." The New England Journal of Medicine 350, no. 22 (May 2004): 2265-2271.  Full Text
    • Zekry, A, Patel, K, Muir, A, and McHutchison, JG. "Tinkering and tailoring with HCV therapy: Can we get away with less?." Hepatology 40, no. 6 (2004): 1249-1251.  Full Text
    • Dev, A, Patel, K, Muir, A, and McHutchison, JG. "Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions." The American Journal of Gastroenterology 98, no. 11 (November 2003): 2344-2347.  Full Text
    • Patel, K, Dev, A, Muir, AJ, and McHutchison, JG. "Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?." Hepatology 38, no. 1 (July 2003): 21-24. (Review)  Full Text  Link to Item
    • Schmidt, TD, and Muir, AJ. "A case of electrical storm in a liver transplant patient." Transplant Proc 35, no. 4 (June 2003): 1437-1438.  Link to Item
    • Heneghan, MA, Tuttle-Newhall, JE, Suhocki, PV, Muir, AJ, Morse, M, Bornstein, JD, Sylvestre, PB, Collins, B, Kuo, PC, and Rockey, DC. "De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 3, no. 5 (May 2003): 634-638.  Full Text
    • Patel, K, Muir, A, McHutchison, JG, and Patton, HM. "A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats." The American Journal of Gastroenterology 98, no. 5 (May 2003): 952-955.  Full Text
    • Patel, K, Muir, AJ, and McHutchison, JG. "Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients." Hepatology 37, no. 5 (May 2003): 1222-. (Letter)  Full Text  Link to Item
    • Thabut, D, Simon, M, Myers, RP, Messous, D, Thibault, V, Imbert-Bismut, F, and Poynard, T. "Noninvasive prediction of fibrosis in patients with chronic hepatitis C." Hepatology (Baltimore, Md.) 37, no. 5 (May 2003): 1220-1221. (Letter)  Full Text
    • Muir, AJ, Sanders, LL, Heneghan, MA, Kuo, PC, Wilkinson, WE, and Provenzale, D. "An examination of factors predicting prioritization for liver transplantation." Liver Transpl 8, no. 10 (October 2002): 957-961.  Full Text  Link to Item
    • Muir, AJ, and Trotter, JF. "A survey of current liver biopsy practice patterns." J Clin Gastroenterol 35, no. 1 (July 2002): 86-88.  Link to Item
    • Serpe, MD, Muir, AJ, and Driouich, A. "Immunolocalization of beta-D-glucans, pectins, and arabinogalactan-proteins during intrusive growth and elongation of nonarticulated laticifers in Asclepias speciosa Torr." Planta 215, no. 3 (July 2002): 357-370.  Full Text
    • Muir, AJ, and Rockey, DC. "Acute HCV: the early bird catches the virus." Gastroenterology 122, no. 4 (April 2002): 1176-1177.  Link to Item
    • Patel, R, and Germer, JJ. "Treatment of acute hepatitis C with interferon alfa-2b." The New England Journal of Medicine 346, no. 14 (April 2002): 1091-1092. (Letter)  Full Text
    • Muir, AJ, and Provenzale, D. "A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection." J Clin Gastroenterol 34, no. 3 (March 2002): 268-271.  Link to Item
    • Muir, AJ, Edwards, LJ, Sanders, LL, Bollinger, RR, Koruda, MJ, Bachwich, DR, and Provenzale, D. "A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis." Am J Gastroenterol 96, no. 5 (May 2001): 1480-1485.  Full Text  Link to Item
    • Muir, AJ, Sanders, LL, Wilkinson, WE, and Schmader, K. "Reducing medication regimen complexity: a controlled trial." Journal of General Internal Medicine 16, no. 2 (February 2001): 77-82.  Full Text
    • Serpe, MD, Muir, AJ, and Keidel, AM. "Localization of cell wall polysaccharides in nonarticulated laticifers of Asclepias speciosa Torr." Protoplasma 216, no. 3-4 (January 2001): 215-226.  Full Text
    • Muir, AJ, Provenzale, D, and Onken, JE. "Fistulous complications in Crohn's disease: Impact on health related quality of life (HRQL) and resource utilization." GASTROENTEROLOGY 118, no. 4 (April 2000): A585-A585.  Full Text  Link to Item
    • Muir, AJ. "The natural history of hepatitis C viral infection." Semin Gastrointest Dis 11, no. 2 (April 2000): 54-61. (Review)  Link to Item
    • Palker, TJ, Muir, AJ, Spragion, DE, Staats, HF, Langlois, A, and Montefiori, DC. "The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope." Virology 224, no. 2 (October 1996): 415-426.  Full Text
    • Palker, TJ, Riggs, ER, Spragion, DE, Muir, AJ, Scearce, RM, Randall, RR, McAdams, MW, McKnight, A, Clapham, PR, and Weiss, RA. "Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins." Journal of Virology 66, no. 10 (October 1992): 5879-5889.
    • Muir, AJ, Bell, D, Jackson, M, Nicoll, JJ, and Millar, AM. "The use of 111In-labelled autologous neutrophils in imaging myocardial infarction." Nucl Med Commun 9, no. 10 (October 1988): 707-711.  Link to Item
    • Henson, JB, Patel, Y, Wilder, J, Zheng, J, Chow, SC, King, LY, and Muir, AJ. "Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis." Digestive Diseases and Sciences .  Full Text

  • Book Sections

    • Jazwinski, AB, and Muir, AJ. "The genetics of virologic response." In Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future, 183-192. January 1, 2012.  Full Text

  • Conference Papers

    • Younossi, ZM, Afendy, A, Stepanova, M, Racila, A, Nader, F, Gomel, R, Safer, R, Lenderking, WR, Skalicky, A, Kleinman, L, Myers, RP, Subramanian, GM, McHutchison, JG, Levy, C, Bowlus, CL, Kowdley, K, and Muir, AJ. "Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO." July 2018.  Full Text
    • Harrison, SA, Abdelmalek, MF, Diehl, AM, Caldwell, S, Shiffman, ML, Ghalib, R, Lawitz, E, Rockey, DC, Schall, REA, Jia, C, McColgan, BJ, Myers, RP, Subramanian, M, McHutchison, JG, Muir, AJ, Ratziu, V, Afdhal, NH, Goodman, ZD, Bosch, J, and Sanyal, AJ. "Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis." October 2017.  Link to Item
    • Muir, AJ, Taghipour, M, Hassanzadeh, E, Sahni, VA, Sainani, N, Ding, D, Jia, C, McColgan, BJ, Chung, C, Myers, RP, Subramanian, M, McHutchison, JG, Goodman, ZD, Eksteen, B, Manns, MP, Chapman, RW, Bowlus, CL, Levy, C, and Tempany-Afdhal, C. "A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC)." 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. Washington, DC. October 20, 2017 - October 24, 2017.: WILEY, October 1, 2017.  Link to Item
    • Muir, AJ, Taghipour, M, Hassanzadeh, E, Sahni, VA, Sainani, N, Shiffman, ML, Ding, D, Jia, C, McColgan, BJ, Myers, RP, Subramanian, M, McHutchison, JG, Goodman, ZD, Eksteen, B, Manns, MP, Levy, C, Bowlus, CL, Chapman, RW, and Tempany-Afdhal, C. "Radiologic progression in primary sclerosing cholangitis (PSC) by two-dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial." 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. Washington, DC. October 20, 2017 - October 24, 2017.: WILEY, October 1, 2017.  Link to Item
    • Tempany-Afdhal, C, Taghipour, M, Behringer, PA, Hassanzadeh, E, Sahni, VA, Sainani, N, Ding, D, Zhang, J, McColgan, BJ, Chung, C, Myers, RP, Subramanian, M, McHutchison, JG, Goodman, ZD, Eksteen, B, Manns, MP, Chapman, RW, Bowlus, CL, Levy, C, and Muir, AJ. "Quantification of biliary tree volume in patients with PSC using three dimensional (3D) reconstruction of magnetic resonance cholangiopancreatography (MRCP): Clinical associations and prognostic significance." 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. Washington, DC. October 20, 2017 - October 24, 2017.: WILEY, October 1, 2017.  Link to Item
    • Sanyal, A, Harrison, SA, Ratziu, V, Abdelmalek, MF, Diehl, AM, Caldwell, SH, Shiffman, ML, Aguilar, R, Jia, C, McColgan, BJ, Natha, M, Myers, RP, Subramanian, M, McHutchison, J, Muir, AJ, Afdhal, NH, Bosch, J, and Goodman, Z. "Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis." April 2017.  Full Text
    • French, D, Huntzicker, EG, Goodman, ZD, Shea, PR, Ding, D, Schall, REA, Smith, V, Subramanian, M, Levy, C, Bowlus, CL, Eksteen, B, Chapman, RW, Muir, AJ, Goldstein, DB, and Myers, RP. "Hepatic expression of lysyl oxidase-like-2 ( LOXL2) in primary sclerosing cholangitis (PSC)." October 2016.  Link to Item
    • Henson, JB, Wilder, JM, Patel, YA, Zheng, J, Chow, S-C, King, LY, and Muir, AJ. "Phenotypic Differences in Primary Sclerosing Cholangitis by Age Group." October 2016.  Link to Item
    • Muir, AJ, Buti, M, Nahass, R, Agarwal, K, Gane, EJ, Strasser, SI, Mangia, A, Calleja, JL, Kersey, K, Moody, S, Brainard, DM, Marotta, P, Bourliere, M, Bacon, B, Freilich, B, and Curry, MP. "Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens." 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). Boston, MA. November 11, 2016 - November 15, 2016.: WILEY, October 1, 2016.  Link to Item
    • Nitsche, B, Miller, S, and Muir, AJ. "Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer." October 2016.  Link to Item
    • Patel, YA, Henson, JB, Wilder, JM, Zheng, J, Chow, S-C, Berg, CL, and Muir, AJ. "The Impact of HLA Serotyping and HLA Matching for PSC, PSC/AIH, AIH, PBC/AIH, and PBC Patients on Post-Liver Transplant Graft Failure: an Analysis of the UNOS Database." October 2016.  Link to Item
    • Sena, AC, Hilton, A, Hurt, CB, Swygard, H, Farel, C, Wohl, D, and Muir, AJ. "Bridging the gap: Facilitating linkage to care for persons identified with chronic hepatitis C infections through a public health program." October 2016.  Link to Item
    • Charlton, MR, Afdhal, NH, Natha, M, Stamm, LM, Lee, SM, Brainard, DM, McHutchison, JG, Watkins, PB, and Muir, AJ. "Detecting DILI in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and-2 Studies." May 2016.  Link to Item
    • Charlton, MR, O'Leary, JG, Bzowej, NH, Muir, AJ, Korenblat, KM, Fenkel, JM, Reddy, KR, Lawitz, E, Schiano, TD, Teperman, LW, Fontana, RJ, Schiff, ER, Fried, MW, Doehle, B, An, D, McNally, J, Osinusi, A, Brainard, DM, McHutchison, JG, Brown, RS, and Curry, MP. "Sofosbuvir/Velpatasvir Fixed Dose Combination For The Treatment Of HCV In Patients With Decompensated liver Disease: The Phase 3 ASTRAL-4 Study." December 2015.  Link to Item
    • Bowlus, CL, Patel, K, Guha, IN, Chapman, RW, Chazouilleres, O, Chalasani, NP, Vierling, JM, Myers, RP, Ding, D, Schall, REA, Subramanian, M, McHutchison, JG, Muir, AJ, Goodman, ZD, and Levy, C. "Validation of serum fibrosis marker panels in patients with primary sclerosing cholangitis (PSC) in a randomized trial of simtuzumab." October 2015.  Link to Item
    • French, D, Goodman, ZD, Huntzicker, EG, Newstrom, D, Karnik, S, Smith, V, Schall, REA, Kanwar, B, Subramanian, M, McHutchison, JG, Muir, AJ, and Myers, RP. "Expression of matrix metalloproteinase 9 (MMP9) and the apoptosis signal-regulating kinase 1 (ASK1) pathway activation marker, phospho-P38 (p-P38), in primary sclerosing cholangitis (PSC)." October 2015.  Link to Item
    • Harrison, SA, Goodman, ZD, Ratziu, V, Loomba, R, Diehl, AM, Lawitz, E, Hinrichsen, H, Bambha, K, Abdelmalek, MF, Myers, RP, Schall, REA, Subramanian, M, McHutchison, JG, Afdhal, NH, and Muir, AJ. "Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH)." October 2015.  Link to Item
    • Manns, MP, Eksteen, B, Shiffman, ML, Levy, C, Kowdley, KV, Montano-Loza, AJ, Janssen, HL, Myers, RP, Ding, D, Subramanian, M, McHutchison, JG, Charlton, MR, Bowlus, CL, Muir, AJ, and Chapman, RW. "Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC)." October 2015.  Link to Item
    • Mayo, MJ, Wigg, AJ, Roberts, SK, Arnold, H, Hassanein, TI, Leggett, BA, Bate, JP, Weltman, M, Carey, EJ, Muir, AJ, McCaughan, G, Bollipo, SJ, Gordon, SC, Angus, PW, Riordan, S, Shiffman, ML, Young, E, Ling, L, Luo, J, Elliott, M, Rossi, S, DePaoli, AM, and Thompson, AJ. "NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial." 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). San Francisco, CA. November 13, 2015 - November 17, 2015.: WILEY-BLACKWELL, October 1, 2015.  Link to Item
    • Mayo, MJ, Wigg, AJ, Thompson, AJ, Roberts, SK, Arnold, H, Hassanein, TI, Leggett, BA, Bate, JP, Weltman, M, Carey, EJ, McCaughan, G, Bollipo, SJ, Gordon, SC, Angus, PW, Riordan, S, Shiffman, ML, Young, E, Ling, L, Luo, J, Elliott, M, Rossi, S, DePaoli, AM, and Muir, AJ. "Impact of NGM282 on the Incidence and Severity of Pruritus in Primary Biliary Cirrhosis Patients and Correlations with Liver Chemistries and Serum Bile Acids." 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). San Francisco, CA. November 13, 2015 - November 17, 2015.: WILEY-BLACKWELL, October 1, 2015.  Link to Item
    • Muir, AJ, Charlton, MR, Pang, PS, Stamm, LM, Brainard, DM, McHutchison, JG, Afdhal, NH, and Watkins, PB. "Detecting Drug-Induced Liver Injury in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies." October 2015.  Link to Item
    • Ratziu, V, Sanyal, AJ, Loomba, R, Caldwell, SH, Ghalib, RH, Torres, DM, McCullough, AJ, Muir, AJ, Myers, RP, Schall, REA, Subramanian, M, McHutchison, JG, Bosch, J, Harrison, SA, and Abdelmalek, MF. "Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH)." October 2015.  Link to Item
    • Reau, N, Muir, AJ, Pockros, P, Reddy, KR, Pedrosa, M, Larsen, L, Enejosa, J, and Howell, C. "High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r plus Dasabuvir +/- Ribavirin: Integrated Safety and Efficacy Analysis." October 2015.  Link to Item
    • Charlton, M, Samuel, D, Gane, E, Jr, BRS, Curry, MP, Kwo, P, Fontana, R, Gilroy, R, Teperman, L, Muir, AJ, McHutchison, JG, Symonds, WT, Denning, J, McNair, L, Arterburn, S, Terrault, N, Forns, X, and Manns, MP. "Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection after Liver Transplantation: Results of a Prospective, Multicenter Study." June 2014.  Link to Item
    • Moylan, CA, Owzar, K, Muir, AJ, Cauchy, F, Belghiti, J, Diehl, AM, and Paradis, V. "Gene Expression and Pathway Analyses Reveal Distinctions Between Hepatocellular Carcinoma Arising in Fibrotic and Non-Fibrotic Nonalcoholic Fatty Liver Disease." May 2014.  Link to Item
    • Brown, CL, Hammill, BG, Qualls, LG, Curtis, LH, and Muir, AJ. "High morbidity and mortality in end-stage liver disease and heart failure." 2014.  Link to Item
    • Jeffers, LJ, Wilder, JM, Muir, AJ, Howell, C, Zhu, Y, Seyedkazemi, S, Yang, JC, Pang, PS, McHutchison, JG, and Reddy, KR. "Safety and Efficacy of Ledipasvir/Sofosbuvir Single-Tablet-Regimen in African Americans with Genotype 1 Chronic Hepatitis C Virus: A Retrospective Analysis of Phase 3 Studies." 2014.  Link to Item
    • Jensen, DM, O'Leary, JG, Pockros, PJ, Sherman, KE, Kwo, PY, Mailliard, ME, Kowdley, KV, Muir, AJ, Dickson, RC, Ramani, A, Manns, MP, Lok, AS, Akuskevich, L, Nelson, DR, and Fried, MW. "Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort." 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases. Boston, MA. November 7, 2014 - November 11, 2014.: WILEY-BLACKWELL, January 1, 2014.  Link to Item
    • Jou, JH, Beste, LA, Yang, Y, Chang, MF, and Muir, AJ. "Specialty Care is Associated with Early Diagnosis of Hepatitis C-related Hepatocellular Carcinoma in US Veterans." 2014.  Link to Item
    • Oloruntoba, OO, Wilder, JM, Smith, AD, Muir, AJ, and Moylan, CA. "The Influence of Race on Patient Preferences and Access to Orthotopic Liver Transplantation and Organ Donation." 2014.  Link to Item
    • Charlton, MR, Gane, EJ, Manns, MP, Brown, RS, Curry, MP, Kwo, PY, Fontana, RJ, Gilroy, R, Teperman, LW, Muir, AJ, McHutchison, JG, Symonds, WT, Denning, JM, McNair, L, Arterburn, S, Terrault, N, Samuel, D, and Forns, X. "Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study." December 2013.  Link to Item
    • Jazwinski, AB, Clark, PJ, Thompson, AJ, Gordon, SC, Lawitz, EJ, Noviello, S, Brass, CA, Pedicone, LD, Albrecht, JK, Sulkowski, MS, and Muir, AJ. "Predictors of consent to pharmacogenomics testing in the IDEAL study." November 2013.  Full Text
    • Gordon, SC, Muir, AJ, Lim, JK, Pearlman, B, Argo, CK, Neff, GW, Ramani, A, Maliakkal, B, Rodriguez-Torres, M, Stewart, T, Fried, MW, and Reddy, KR. "The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study." October 2013.  Link to Item
    • Muir, AJ, Jurkowski, C, Cooney, EL, Hillson, JL, Lataillade, M, Casullo, VM, Gray, T, Xu, D, Yogendran, L, and Srinivasan, S. "Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies." October 2013.  Link to Item
    • Afdhal, N, Giannini, EG, Sigal, S, Muir, AJ, Reddy, KR, Sheen, I-S, Vijayaraghavan, S, Elkashab, M, Romero-Gomez, M, Dusheiko, G, Iyengar, M, Vasey, SY, Campbell, FM, and Theodore, D. "Improved SVR in a unique cohort of non-cirrhotic thrombocytopenic patients with hepatitis C virus (HCV) treated in the global multicenter ENABLE 1 and 2 trials." October 2012.  Link to Item
    • Clark, PJ, Santoro, R, Piazzolla, V, Mottola, L, Bacca, D, Dello Iacono, N, Grimaldi, S, Quarta, A, Urban, TJ, Naggie, S, Patel, K, Thompson, AJ, Muir, AJ, and Mangia, A. "Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C." October 2012.  Link to Item
    • Devine, S, Kattan, MW, Muir, AJ, Pedicone, L, Poordad, F, Poynard, T, Sulkowski, MS, and Thompson, AJ. "Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR)." October 2012.  Link to Item
    • Jones, L, Cox, N, Konadu, S, Brinson, SW, and Muir, AJ. "Automated Extraction of Quality Indicators for Hospitalized patients with cirrhosis and ascites." October 2012.  Link to Item
    • Muir, AJ, Hillson, JL, Gray, TE, Xu, D, Ishak, L, Freeman, JA, Fontana, D, Horga, A, and Lopez-Talavera, JC. "Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b." October 2012.  Link to Item
    • Muir, AJ, Rodriguez-Torres, M, Borroto-Esoda, K, Peel, M, Hopkins, S, and Ribeill, Y. "Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients." October 2012.  Link to Item
    • Muir, AJ, Srinivasan, S, Sapra, S, Dimitrova, D, Hillson, JL, and Lopez-Talavera, JC. "Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa)." October 2012.  Link to Item
    • Saraswathula, A, Wilder, JM, and Muir, AJ. "A Systematic Review of Racial and Ethnic Diversity of Hepatitis C Virus Clinical Trials." October 2012.  Link to Item
    • Shiffman, ML, Muir, AJ, Vierling, JM, Gordon, SC, Kugelmas, M, Wu, GY, Nguyen, TT, Balart, LA, McHutchison, JG, Armstrong, BR, Mann, DL, Guo, Z, King, TH, Ferraro, J, Mattson, A, Rodell, TC, and Apelian, D. "GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T." October 2012.  Link to Item
    • Thompson, AJ, Shiffman, ML, Rossaro, L, Ghalib, R, Han, S-HB, Beavers, KL, Pianko, S, George, J, He, L, Wu, X, Flores, N, Pang, PS, Rossi, SJ, McHutchison, JG, Lee, SS, and Muir, AJ. "Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial." October 2012.  Link to Item
    • Clark, PJ, Thompson, AJ, Jazwinski, A, Tillmann, HL, Naggie, S, Muir, AJ, and Patel, K. "Association of Serum Adipocytokines With IL28B and SVR in Chronic Hepatitis C." Digestive Disease Week (DDW). San Diego, CA. May 19, 2012 - May 22, 2012.: W B SAUNDERS CO-ELSEVIER INC, May 1, 2012.  Link to Item
    • Clark, PJ, Thompson, AJ, Urban, TJ, Patel, K, Vock, DM, Zhu, Q, Jazwinski, A, Naggie, S, Tillmann, HL, McKenzie, A, Conjeevaram, HS, Shianna, K, Goldstein, DB, Afdhal, NH, and Muir, AJ. "PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC)." October 2011.  Link to Item
    • Clark, PJ, Thompson, AJ, Vock, DM, Kratz, LE, Tolun, AA, Zhang, HY, Muir, AJ, Subramanian, M, McHutchison, JG, Millington, DS, Kelley, RI, and Patel, K. "METABOLOMIC ANALYSIS DEMONSTRATES HEPATITIS C VIRUS GENOTYPES G2/3 SELECTIVELY PERTURB DISTAL STEPS IN CHOLESTEROL BIOSYNTHESIS." October 2011.  Link to Item
    • Gellad, ZF, Naggie, S, Reed, SD, Clark, PJ, Thompson, AJ, Schulman, KA, and Muir, AJ. "THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM." October 2011.  Link to Item
    • Jazwinski, A, Clark, PJ, Tillmann, HL, Muir, AJ, and Jazwinski, A. "VITAMIN D AND TREATMENT RESPONSE IN AFRICAN AMERICAN PATIENTS WITH HCV GENOTYPE 1." October 2011.  Link to Item
    • Muir, AJ, Bacon, BR, Gitlin, N, Kugelmas, M, Tillman, HL, Grovender, EA, Van Antwerp, B, Mische, S, and Kwo, PY. "INTERFERON alpha-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS." October 2011.  Link to Item
    • Rabiee, A, Tillmann, HL, Poordad, FF, Lawitz, E, Shiffman, ML, Muir, AJ, Noviello, S, Brass, CA, Pedicone, L, Albrecht, JK, Sulkowski, MS, and Jacobson, IM. "INFLUENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE-1 (G1) SUBTYPE, BASELINE VIRAL LOAD AND IL28B GENOTYPE ON PEGINTERFERON (PEG)/RIBAVIRIN (RBV) TREATMENT RESPONSE: RESULTS OF THE IDEAL STUDY." October 2011.  Link to Item
    • Thompson, AJ, Clark, PJ, Tillmann, HL, Patel, K, Naggie, S, Poordad, FF, Lawitz, E, Bacon, BR, Vierling, JM, Noviello, S, Brass, CA, Albrecht, JK, Goldstein, DB, McHutchison, JG, Sulkowski, MS, and Muir, AJ. "IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS." October 2011.  Link to Item
    • Thompson, AJ, Clark, PJ, Vock, DM, Pfeiffer, R, Tillmann, HL, Patel, K, Naggie, S, Poordad, FF, Nyberg, LM, Noviello, S, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, McHutchison, JG, O'Brien, TR, Sulkowski, MS, and Muir, AJ. "PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS." October 2011.  Link to Item
    • Smith, AD, Muir, AJ, Morse, MA, Suhocki, PV, and Ravindra, KV. "Liver Transplantation Following Down-Staging of a Large Primary Liver Tumor Associated with a Very High Serum Alpha Fetoprotein Concentration." June 2011.  Link to Item
    • Gellad, ZF, Reed, S, Muir, AJ, McHutchison, J, Steven, W, Sharara, AI, Brown, KAA, Flisiak, R, Jacobson, IM, Kershenobich, D, Manns, MP, and Schulman, KA. "Truncated Therapy Based on Rapid Virologic Response is a Cost Effective Treatment Paradigm for Chronic Hepatitis C." May 2011.  Link to Item
    • Clark, PJ, Thompson, AJ, Zhu, M, Zhu, Q, Ge, D, Sulkowski, MS, Tillmann, HL, Patel, K, Naggie, S, Muir, AJ, Afdhal, NH, Jacobson, IM, Esteban, R, Lawitz, E, Poordad, F, Shiffman, ML, Galler, GW, Harrison, S, King, JW, Kwo, PY, Nyberg, LM, McCone, J, Lee, WM, Reindollar, R, Ghalib, RH, Freilich, B, Goodman, Z, Boparai, N, Koury, KJ, Noviello, S, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "IL28B GENETIC POLYMORPHISM HAS GENOME WIDE SIGNIFICANT ASSOCIATIONS WITH SERUM LOW DENSITY LIPOPROTEIN LEVELS AND HEPATIC STEATOSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC)." October 2010.  Link to Item
    • Jacobson, IM, McHutchison, JG, Dusheiko, GM, Di Bisceglie, AM, Reddy, R, Bzowej, NH, Marcellin, P, Muir, AJ, Bengtsson, L, Dunne, AM, Adda, N, George, S, Kauffman, RS, and Zeuzem, S. "TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY." October 2010.  Link to Item
    • Lawitz, E, Rodriguez-Torres, M, Rustgi, VK, Hassanein, T, Rahimy, MH, Crowley, CA, Freddo, JL, Muir, AJ, and McHutchison, JG. "SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS." October 2010.  Link to Item
    • Muir, AJ, Lawitz, E, Ghalib, RH, Sussman, NL, Anderson, F, Everson, GT, Jacobson, IM, Lopez-Talavera, JC, Hillson, JL, Gray, TE, Fontana, D, Ramos, EL, and Rodriguez-Torres, M. "PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12." October 2010.  Link to Item
    • Muir, AJ, Lawitz, E, Rodriguez-Torres, M, Rustgi, VK, Hassanein, T, Appleman, JR, Crowley, CA, Freddo, JL, and McHutchison, JG. "IL28B POLYMORPHISM AND KINETICS OF ANTIVIRAL ACTIVITY FOR ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 CHRONIC HCV PATIENTS." October 2010.  Link to Item
    • Muir, AJ. "SS7-5 Genetic variation in IL28B and hepatitis C outcomes." : Elsevier BV, October 2010.  Full Text
    • Rodriguez-Torres, M, Ghalib, RH, Gordon, SC, Lawitz, E, Patel, K, Pruitt, R, Sheikh, AM, Arbeit, RD, Bexon, AS, Kandimalla, ER, Precopio, M, Sullivan, T, Muir, AJ, and McHutchison, JG. "IMO-2125, A TLR9 AGONIST, INDUCES IMMUNE RESPONSES WHICH CORRELATE WITH REDUCTIONS IN VIRAL LOAD IN NULL RESPONDER HCV PATIENTS." 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases. Boston, MA. October 29, 2010 - November 2, 2010.: WILEY-BLACKWELL, October 1, 2010.  Link to Item
    • Sulkowski, MS, Harrison, SA, Rossaro, L, Hu, K-Q, Lawitz, E, Shiffman, ML, Muir, AJ, Galler, GW, McCone, J, Nyberg, LM, Lee, WM, Ghalib, RH, Long, J, Noviello, S, Brass, CA, Pedicone, L, Albrecht, JK, McHutchison, JG, and King, JW. "IMPAIRED FASTING GLUCOSE IS ASSOCIATED WITH LOWER RATES OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC): RETROSPECTIVE ANALYSIS OF THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Clark, PJ, Fellay, J, Muir, AJ, Tillmann, HL, Patel, K, Naggie, S, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, LM, Goodman, Z, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, McHutchison, JG, and Sulkowski, MS. "IL28B GENOTYPE IS NOT ASSOCIATED WITH ADVANCED HEPATIC FIBROSIS IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Clark, PJ, Singh, A, Ge, D, Fellay, J, Sulkowski, MS, Muir, AJ, Tillman, HL, Patel, K, Naggie, S, Shianna, K, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, L, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "COMMON GENETIC VARIANTS DO NOT ASSOCIATE WITH IFN-INDUCED NEUTROPENIA IN A GENOME-WIDE ASSOCIATION STUDY OF CHRONIC HEPATITIS C PATIENTS IN THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Clark, PJ, Zhu, M, Zhu, Q, Ge, D, Sulkowski, MS, Muir, AJ, Tillmann, HL, Patel, K, Naggie, S, Afdhal, NH, Jacobsons, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, LM, Goodman, Z, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, C, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "GENOME WIDE-ASSOCIATION STUDY IDENTIFIES IL28B POLYMORPHISM TO BE ASSOCIATED WITH BASELINE ALT AND HEPATIC NECRO-INFLAMMATORY ACTIVITY IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY." October 2010.  Link to Item
    • Thompson, AJ, Muir, AJ, Sulkowski, MS, Patel, K, Tillmann, HL, Clark, PJ, Naggie, S, Fellay, J, Ge, D, McCarthy, J, Goldstein, DB, and McHutchison, JG. "HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE." October 2010.  Link to Item
    • Thompson, AJ, Singh, A, Fellay, J, Ge, D, Sulkowski, MS, Muir, AJ, Tillmann, HL, Patel, K, Naggie, S, Shianna, K, Afdhal, NH, Jacobson, IM, Esteban, R, Poordad, F, Lawitz, E, McCone, J, Shiffman, ML, Galler, GW, King, JW, Kwo, PY, Nyberg, LM, Noviello, S, Boparai, N, Koury, KJ, Pedicone, L, Brass, CA, Albrecht, JK, Goldstein, DB, and McHutchison, JG. "GENOME-WIDE ASSOCIATION STUDY IDENTIFIES AN ASSOCIATION BETWEEN ITPA GENE VARIANTS AND IFN-INDUCED THROMBOCYTOPENIA IN CHRONIC HEPATITIS C PATIENTS FROM THE IDEAL STUDY." October 2010.  Link to Item
    • Lawitz, E, Muir, AJ, Poordod, F, Chun, E, and Hammond, J. "TREATMENT WEEK 24 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAiVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS." October 2008.  Link to Item
    • Lawitz, EJ, Zaman, A, Muir, AJ, Shiffman, ML, Yoffe, B, Zhang, T, Souza, S, and Hausman, DF. "INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN." October 2008.  Link to Item
    • McCone, J, Hu, K-Q, McHutchison, JG, Shiffman, ML, King, JW, Herrine, SK, Goller, GW, Sulkowski, M, Nunes, F, Brown, KAA, Gordon, SC, Mullen, KD, Ravendhran, N, Cassidy, WM, Ghalib, RH, Deng, W, Noviello, S, Albrecht, JK, and Muir, AJ. "SUSTAINED VIROLOGIC RESPONSE (SVR) AND PREDICTORS OF RESPONSE IN AFRICAN AMERICAN (AA) PATIENTS IN THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE 3B STUDY." October 2008.  Link to Item
    • McHutchison, JG, Shiffman, ML, Terrault, N, Manns, MP, Di Bisceglie, AM, Jacobson, IM, Afdhal, NH, Heathcote, EJ, Zeuzem, S, Reesink, HW, George, S, Adda, N, and Muir, AJ. "A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS." October 2008.  Link to Item
    • Moylan, CA, Choi, SS, Acharya, CR, Salter, K, Muir, AJ, Potti, A, and Diehl, AM. "GENE EXPRESSION PROFILES COUPLED WITH SIGNATURES OF ONCOGENIC PATHWAY DYSREGULATION PROVIDE A RATIONAL APPROACH TO DISSECTING THE MOLECULAR HETEROGENEITY OF HEPATOCELLULAR CARCINOMA." October 2008.  Link to Item
    • Muir, AJ, Lawitz, EJ, McHutchison, JG, Gordon, SC, Jacobson, IM, Adiwijaya, BS, Bengtsson, L, McNair, L, and Rodriguez-Torres, M. "VIRAL RESPONSES IN AFRICAN-AMERICANS, LATINOS AND CAUCASIANS IN THE US PHASE 2 STUDY (PROVE1) OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAME GENOTYPE 1-INFECTED SUBJECTS WITH HEPATITIS C." October 2008.  Link to Item
    • Nyberg, LM, Shiffman, ML, Bonilla, H, Hu, K-Q, Morgan, TR, Levine, RA, Lawitz, EJ, McHutchison, JG, Muir, AJ, Galler, GW, McCone, J, Lee, WM, Ghalib, RH, Schiff, ER, Galati, JS, Bacon, BR, Davis, M, Herrine, SK, Gibas, AL, Freilich, B, King, JW, Rossaro, L, Sulkowski, MS, Mukhopadhyay, P, Noviello, S, Albrecht, JK, and Poordad, F. "PREDICTING THE ABILITY TO ACHIEVE A SUSTAINED VIROLOGIC RESPONSE (SVR) IN THE FIRST 12 WEEKS: RESULTS FROM THE IDEAL STUDY." October 2008.  Link to Item
    • Poordad, F, Brau, N, Lawitz, EJ, Shiffman, ML, McHutchison, JG, Muir, AJ, Galler, GW, McCone, J, Nyberg, LM, Lee, WM, Ghalib, RH, Schiff, ER, Galati, JS, Bacon, BR, Davis, M, Herrine, SK, Gibas, AL, Freilich, B, King, JW, Rossaro, L, Mukhopadhyay, P, Noviello, S, Brass, CA, Albrecht, JK, and Sulkowski, MS. "HEMATOLOGIC SAFETY DATA FROM THE IDEAL TRIAL: NEUTROPENIA, ANEMIA AND THROMBOCYTOPENIA PROFILES OF PEGINTERFERON ALFA/RIBAVIRIN." October 2008.  Link to Item
    • Shiffman, ML, Berg, T, Poordad, FF, Bronowicki, J-P, Muir, AJ, Gordon, SC, George, S, Adda, N, and McHutchison, JG. "A STUDY OF TELAPREVIR COMBINED WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN SUBJECTS WITH WELL-DOCUMENTED NON-RESPONSE OR RELAPSE AFTER PREVIOUS PEGINTERFERON-ALFA-2A AND RIBAVIRIN TREATMENT: INTERIM ANALYSIS." October 2008.  Link to Item
    • Gentile, JW, Shanahan, JC, Muir, AJ, and Smith, AD. "DISTAL SYMMETRICAL MYOPATHY IN THE SETTING OF PEGYLATED INTERFERON ALFA AND RIBAVIRIN THERAPY FOLLOWING LIVER TRANSPLANTATION." July 2008.  Link to Item
    • Smith, AD, Gentile, JW, Muir, AJ, and Howell, DN. "DE NOVO AUTOIMMUNE HEPATITIS IN THE AFTER MATH OF SUCCESSFUL COMBINATION ANTI-VIRAL THERAPY FOR RECURRENT HEPATITIS C VIRUS LIVER DISEASE." July 2008.  Link to Item
    • Lee, NM, Muir, AJ, and Brady, CW. "The Readability of Hepatitis C Health Education Materials." : Ovid Technologies (Wolters Kluwer Health), September 2007.  Full Text
    • Robertson, KD, Moylan, CA, Brady, CW, and Muir, AJ. "Factors Influencing Participation in Hepatitis C Research Trials." : Ovid Technologies (Wolters Kluwer Health), September 2007.  Full Text
    • Brady, CW, Smith, AD, Stechuchak, KM, Coffman, CJ, Tuttle-Newhall, JE, Provenzale, D, and Muir, AJ. "Predictors of the development of de novo hepatocellular carcinoma (HCC) in patients awaiting orthotopic liver transplantation (OLT) during the meld era." October 2006.  Link to Item
    • Gellad, ZF, Alexander, BD, Liu, JK, Griffith, BC, Meyer, AM, Johnson, JL, and Muir, AJ. "Severity of Clostridium difficile associated diarrhea in solid-organ transplant patients." September 2006.  Link to Item
    • Muir, AJ, McHutchison, JG, Patel, K, Clary, G, and Gagliardi, JP. "Sertaline for the prevention of depression with HCV therapy." September 2006.  Link to Item
    • Muir, AJ, Sylvestre, PB, and Rockey, DC. "Interferon gamma-1b for the treatment of chronic hepatitis C infection." April 2003.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.